Published

Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of psychopharmacology (Oxford, England)
Date: 2018-12-01
Source: PubMed
DOI: 10.1177/0269881118793086
PubMed: 30182795

Authors

Leonard JB Anderson B Klein-Schwartz W

Watch author

Derived topics and classifications

psilocybin Adolescents Safety Toxicity Other

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations2026-07-21 Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016.2018-12-01

Related papers

Commentary on Darke et al.: Expanded psychedelic access requires new safety monitoring systems.Addiction (Abingdon, England) · 2024-09-01 Exposure to Potent Hallucinogens in an AdolescentThe Primary Care Companion For CNS Disorders · 2013-10-23 Classic psychedelic medicines for adolescent refractory mental health diseaseJournal of Psychedelic Studies · 2026-03-26 Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.ClinicalTrials.gov · 2025-11-19 The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.ClinicalTrials.gov · 2025-09-15 A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-08-14 Processing Intergenerational Trauma With Psilocybin-Assisted TherapyClinicalTrials.gov · 2026-08-13 PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-08-13